Department of Obstetrics and Gynecology, Eastern Virginia Medical School, CONRAD Clinical Research Center, 601 Colley Ave., Norfolk, VA 23507, USA.
Am J Obstet Gynecol. 2010 Feb;202(2):139.e1-6. doi: 10.1016/j.ajog.2009.09.031. Epub 2009 Dec 3.
We sought to determine the sensitivity and specificity of alternative monitoring regimens in predicting the need for a second methotrexate (MTX) dose in women undergoing medical therapy for ectopic pregnancy.
We reviewed 187 women who received MTX for ectopic pregnancy.
We defined MTX treatment success as a clinically stable patient whose day-7 beta human chorionic gonadotropin (beta-hCG) level decreased by > or = 50%, compared with the day-of-treatment (DOT) beta-hCG. In comparison to the standard MTX monitoring protocol, this model was 100% sensitive and 57.4% specific in predicting the need for a second MTX dose in women whose DOT beta-hCG was <2000 mIU/mL and was 100% sensitive and 37.9% specific in women whose DOT beta-hCG was > or = 2000 mIU/mL.
This model is an alternative to the traditional MTX monitoring regimen.
我们旨在确定替代监测方案在预测需要第二次甲氨蝶呤（MTX）剂量的异位妊娠女性中的敏感性和特异性。
我们回顾了 187 名接受 MTX 治疗异位妊娠的女性。
我们将 MTX 治疗成功定义为临床稳定的患者，其第 7 天β人绒毛膜促性腺激素（β-hCG）水平与治疗日（DOT）β-hCG相比下降≥50%。与标准 MTX 监测方案相比，在 DOTβ-hCG<2000 mIU/mL 的女性中，该模型的敏感性为 100%，特异性为 57.4%，在 DOTβ-hCG≥2000 mIU/mL 的女性中，敏感性为 100%，特异性为 37.9%。
该模型是传统 MTX 监测方案的替代方案。
